Clinical global impression (response rate) ‐ desipramine · Children and adolescents with ADHD
Tricyclic antidepressants (TCAs) may leads to higher clinical global impression (response rate) ‐ desipramine compared with placebo (low certainty).
1 finding from 1 review
Preterm birth · pregnant women
Summary of findings: lipid‐based nutrient supplements (LNS) showed no clear difference in preterm births (births before 37 weeks of gestation) compared with multiple micronutrients (MMN) (moderate certainty).
1 finding from 1 review
Preterm birth · pregnant women
Summary of findings: lipid‐based nutrient supplements (LNS) showed no clear difference in preterm births (births before 37 weeks of gestation) compared with iron folic acid (IFA) (moderate certainty).
1 finding from 1 review
Efficacy for ADHD symptoms (parents using a rating scale) ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Efficacy for ADHD symptoms (teachers using a rating scale) ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
CGI (response rate) ‐ desipramine and nortriptyline · Children and adolescents with ADHD
Tricyclic antidepressants (TCAs) may leads to higher CGI (response rate) ‐ desipramine and nortriptyline compared with placebo (low certainty).
1 finding from 1 review
All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
Antidepressants may leads to higher adverse effects compared with placebo (low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Antidepressants may leads to higher attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Deliberate self‐harm · patients with borderline personality disorder
1 finding from 1 review
Adverse events · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aggression · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reconviction · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found